Acute Leukemias II: Prognostic Factors and Treatment Strategies
Thomas Büchner, Günther Schellong, Wolfgang Hiddemann, Jörg Ritter
Springer Berlin Heidelberg, Jan 19, 1990 - Medical - 776 pages
Acute leukemia a quite homogenous disease failed to break through the sound barriere of when untreated reveals a substantial hetero unsatisfactory cure rates even in special sub geneity in its response to therapy. While cure groups. While new protocols including more is achieved in a certain proportion of pa effective supportive care show some increase tients other cases prove to be highly resis in the initial response rates and certain im tant. The curability is superior in acute provements in the long-term results, no ben lymphoblastic (ALL) than in acute myeloid eficial effect on the relapse rate during the (AML) leukemia and - within both type- first 1 Y2 years emerged from any of these higher in children as compared to adults. regimens. Thus, high chances for cure are The two age groups and cell types can be presently restricted to children with ALL further subdivided into prognostic groups and to lesser proportions children with by special diagnostic features. Thus, in AML and adults with ALL and AML.
65 pages matching antigen in this book
Results 1-3 of 65
What people are saying - Write a review
We haven't found any reviews in the usual places.
Preleukemic or Early
Clonal Analysis of Human Leukemias by Molecular
Lessons Learned from Animal Models
15 other sections not shown
Other editions - View all
33 Acute Leukemias abnormalities acute leukemia acute lymphoblastic leukemia acute myelogenous leukemia acute myeloid leukemia allogeneic analysis ANLL antigen Ara-C autologous bone marrow Berlin Heidelberg 1990 blast cells Blood Transfusion Vol bone marrow transplantation Cancer chemotherapy childhood acute chromosome Clin Oncol clinical complete remission consolidation therapy cytarabine cytogenetic cytosine arabinoside cytotoxic daunorubicin diagnosis disease disease-free survival dose drug duration Edited by Buchner effects etoposide evaluated gene GM-CSF granulocyte GVHD Haematol hematological Hiddemann induction therapy infections irradiation karyotype kemia Leukemias II Edited leukemic cells lymphocytic maintenance markers median methotrexate mitoxantrone months myelodysplastic myelodysplastic syndromes normal patients received patients with acute Pediatrics phase platelet prognostic factors protocol randomized recombinant refractory regimen rhGM-CSF risk Ritter Schellong Springer-Verlag Berlin Heidelberg subtypes syndromes T-cell Table tients tion toxicity treated treatment trial tumor vitro